| Literature DB >> 25847241 |
Ramakrishna Edukulla1, Brijendra Singh1, Anil G Jegga2, Vishwaraj Sontake1, Stacey R Dillon3, Satish K Madala4.
Abstract
Interleukin 31 receptor α (IL-31RA) is a novel Type I cytokine receptor that pairs with oncostatin M receptor to mediate IL-31 signaling. Binding of IL-31 to its receptor results in the phosphorylation and activation of STATs, MAPK, and JNK signaling pathways. IL-31 plays a pathogenic role in tissue inflammation, particularly in allergic diseases. Recent studies demonstrate IL-31RA expression and signaling in non-hematopoietic cells, but this receptor is poorly studied in immune cells. Macrophages are key immune-effector cells that play a critical role in Th2-cytokine-mediated allergic diseases. Here, we demonstrate that Th2 cytokines IL-4 and IL-13 are capable of up-regulating IL-31RA expression on both peritoneal and bone marrow-derived macrophages from mice. Our data also demonstrate that IL-4Rα-driven IL-31RA expression is STAT6 dependent in macrophages. Notably, the inflammation-associated genes Fizz1 and serum amyloid A (SAA) are significantly up-regulated in M2 macrophages stimulated with IL-31, but not in IL-4 receptor-deficient macrophages. Furthermore, the absence of Type II IL-4 receptor signaling is sufficient to attenuate the expression of IL-31RA in vivo during allergic asthma induced by soluble egg antigen, which may suggest a role for IL-31 signaling in Th2 cytokine-driven inflammation and allergic responses. Our study reveals an important counter-regulatory role between Th2 cytokine and IL-31 signaling involved in allergic diseases.Entities:
Keywords: STAT6; Th2 cytokines; allergic asthma; asthma; cytokine; inflammation; interleukin-31; macrophage; signaling
Mesh:
Substances:
Year: 2015 PMID: 25847241 PMCID: PMC4505597 DOI: 10.1074/jbc.M114.622126
Source DB: PubMed Journal: J Biol Chem ISSN: 0021-9258 Impact factor: 5.157